Investec Asset Management North America Inc. grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 7.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,852 shares of the medical equipment provider’s stock after buying an additional 1,565 shares during the period. Investec Asset Management North America Inc.’s holdings in Hologic were worth $1,082,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. PNC Financial Services Group Inc. raised its holdings in shares of Hologic by 4.4% in the second quarter. PNC Financial Services Group Inc. now owns 207,956 shares of the medical equipment provider’s stock worth $9,435,000 after buying an additional 8,674 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Hologic by 11.8% in the second quarter. ProShare Advisors LLC now owns 153,243 shares of the medical equipment provider’s stock worth $6,954,000 after buying an additional 16,119 shares during the last quarter. Profund Advisors LLC raised its holdings in shares of Hologic by 4.4% in the second quarter. Profund Advisors LLC now owns 26,993 shares of the medical equipment provider’s stock worth $1,225,000 after buying an additional 1,132 shares during the last quarter. Laurion Capital Management LP raised its holdings in shares of Hologic by 837.1% in the second quarter. Laurion Capital Management LP now owns 119,944 shares of the medical equipment provider’s stock worth $5,443,000 after buying an additional 107,144 shares during the last quarter. Finally, BlueMountain Capital Management LLC raised its holdings in shares of Hologic by 26.5% in the second quarter. BlueMountain Capital Management LLC now owns 25,180 shares of the medical equipment provider’s stock worth $1,143,000 after buying an additional 5,270 shares during the last quarter. 96.38% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/18/hologic-inc-holx-shares-bought-by-investec-asset-management-north-america-inc.html.

In other Hologic news, Director Lawrence M. Levy sold 7,139 shares of the company’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $39.04, for a total transaction of $278,706.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the company’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the transaction, the director now owns 23,810 shares of the company’s stock, valued at approximately $955,257.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 27,594 shares of company stock valued at $1,168,871. 0.79% of the stock is owned by insiders.

A number of research analysts have issued reports on HOLX shares. Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a report on Tuesday, August 1st. BidaskClub cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $51.00 price target on shares of Hologic in a report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a report on Friday, July 14th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $49.00 price target on shares of Hologic in a report on Wednesday, June 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $48.64.

Hologic, Inc. (NASDAQ HOLX) traded down 0.11% during mid-day trading on Monday, reaching $37.68. 330,722 shares of the company traded hands. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The firm has a market capitalization of $10.57 billion, a price-to-earnings ratio of 14.03 and a beta of 0.92. The stock’s 50 day moving average price is $38.90 and its 200 day moving average price is $42.58.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a net margin of 25.65% and a return on equity of 23.18%. The firm had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. During the same quarter in the prior year, the firm earned $0.51 EPS. Hologic’s revenue for the quarter was up 12.4% on a year-over-year basis. Equities analysts forecast that Hologic, Inc. will post $2.01 EPS for the current year.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.